Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. Moulder S, et al. Among authors: wheler j. Invest New Drugs. 2010 Oct;28(5):634-40. doi: 10.1007/s10637-009-9273-1. Epub 2009 Jun 6. Invest New Drugs. 2010. PMID: 19499186 Clinical Trial.
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Hong DS, et al. Among authors: wheler jj. Clin Cancer Res. 2009 Nov 15;15(22):7061-8. doi: 10.1158/1078-0432.CCR-09-1241. Epub 2009 Nov 10. Clin Cancer Res. 2009. PMID: 19903778 Free PMC article. Clinical Trial.
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Ganesan P, et al. Among authors: wheler jj. Mol Cancer Ther. 2014 Dec;13(12):3175-84. doi: 10.1158/1535-7163.MCT-14-0358. Epub 2014 Sep 24. Mol Cancer Ther. 2014. PMID: 25253784 Free PMC article.
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. Falchook GS, et al. Among authors: wheler jj. Invest New Drugs. 2015 Feb;33(1):177-86. doi: 10.1007/s10637-014-0173-7. Epub 2014 Oct 18. Invest New Drugs. 2015. PMID: 25323060 Free PMC article. Clinical Trial.
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Bilen MA, et al. Among authors: wheler jj. Cancer Chemother Pharmacol. 2015 Apr;75(4):869-74. doi: 10.1007/s00280-015-2695-x. Epub 2015 Feb 10. Cancer Chemother Pharmacol. 2015. PMID: 25666183 Clinical Trial.
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.
Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Hong DS, et al. Among authors: wheler jj. Invest New Drugs. 2015 Jun;33(3):621-31. doi: 10.1007/s10637-015-0226-6. Epub 2015 Mar 31. Invest New Drugs. 2015. PMID: 25822109 Free PMC article. Clinical Trial.
150 results